NEW YORK – Blood-based cancer early detection firm Freenome announced a biomarker discovery deal with ADC Therapeutics this week, marking a significant shift to its business. The partners will use Freenome's multi-omics platform to develop methods to identify diffuse large B-cell lymphoma patients (DLBCL) most likely to respond to treatment with the pharma firm’s antibody-drug conjugate loncastuximab tesirine (ADCT-402).
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.